The SAD treatman alone has a potential of peak revenues of around 1.6 billion usd p.a. in the USA alone. The market introduction is forecasted after potential phase 3 in 2026. There are no side effects for this treatment. Cash reach for the company is forecasted after the both readouts. Very interesting. Maybe an outlicensing deal after sucessful phase 2 or a takeover